Fueling an Epidemic: A Flood of 1.6 Billion Doses of Opioids into Missouri and the Need for Stronger DEA Enforcement

Thumbnail Image
Serial Number
Levin Center Identifier
Document Date
Report Length
36 pages
Policy Agendas Project Major Code
Additional, Minority, Dissenting Views
Found Using Methodology
Idependent Author(s)
Brief Executive Summary
At the request of Ranking Member Claire McCaskill, the Democratic staff of the Committee on Homeland Security and Governmental Affairs conducted an examination of the efforts McKesson, AmerisourceBergen, Cardinal Health, Mallinckrodt, and Endo have undertaken to meet their obligations under the CSA, as well as the suspicious order reports these companies have provided to DEA for Missouri orders between 2012 and 2017. The three major pharmaceutical distributors in the United States-McKesson Corporation, AmerisourceBergen Corporation, and Cardinal Health, Inc. each recorded 2017 revenue in excess of $125 billion and ranked within the top 15 companies on the 2017 Fortune 500 list. Although unknown to many Americans, these companies play a critical role in preventing the diversion of opioid products from pharmacies and other customers to the black market.
Press Releases and Contextual Information
Related Hearings
Authors–Congress Members
Authors–Staff Members
Authors–Ex Officio Members
Authors–Additional, Minority, Dissenting Views